Hjem › B-celle lymfom › Texas
B-celle lymfom kliniske forsøg i Texas
26 studier for B-celle lymfom søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RekruttererObservationsstudie
Alder 0 til 38 · Alle køn · Opdateret 1. okt. 2026 · NCT06131801A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Md Anderson Cancer Center, Houston
- Texas Oncology Austin Midtown, Round Rock
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07439653A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06213311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT05615636A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
RekruttererFase 1
Alder 0 til 18 · Alle køn · Opdateret 16. sep. 2026 · NCT06173518Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Austin
- Research Site, Houston
- Research Site, San Antonio
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- The University of Texas Md Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06634589A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06393738Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Texas Oncology - West Texas, Midland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 31. aug. 2026 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Texas Oncology - Northeast, Tyler
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07520006Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05254743Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 til 80 · Alle køn · Opdateret 7. aug. 2026 · NCT05092451A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
- The University of Texas M D Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. jul. 2026 · NCT05773040DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
- MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT06792734Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- The University of Texas M. D. Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. maj 2026 · NCT07283679The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- SCRI, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. nov. 2025 · NCT05643742Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
- Sarah Cannon - St. David South Austin Medical Center, Austin
RekruttererFase 1/2
Alder 18 til 80 · Alle køn · Opdateret 24. aug. 2025 · NCT05607420Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.